Curriculum Vitaes
  1. Researcher Search Results
  2. senju hashimoto

senju hashimoto

  (橋本 千樹)

Profile Information

Affiliation
Clinical Professor, School of Medicine Department of Gastroenterology and Hepatology, Fujita Health University
Degree
博士(医学)
J-GLOBAL ID
201501020246836172
researchmap Member ID
7000012760

Major Research Interests

 3
More

Research Areas

 1

Research History

 2

Papers

 433
  • Hisanori Muto, Teiji Kuzuya, Naoto Kawabe, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Senju Hashimoto, Yoshiaki Katano, Yoshiki Hirooka
    Anticancer research, 43(10) 4673-4682, Oct, 2023  
    BACKGROUND/AIM: The combination of atezolizumab plus bevacizumab (Atz/Bev) has become widely used as a first-line therapy for advanced hepatocellular carcinoma (HCC). However, for post-Atz/Bev therapy, evidence on the outcomes of molecular targeted agents, such as lenvatinib, is limited. The present study aimed to assess the clinical effectiveness of lenvatinib on advanced HCC in patients who had previously undergone Atz/Bev treatment. PATIENTS AND METHODS: Twenty patients with HCC, who received lenvatinib after Atz/Bev treatment, were enrolled in the study. In particular, we examined the impact of adverse events (AEs), such as anorexia and general fatigue. During the treatment, lenvatinib dosages were adjusted or temporarily discontinued in response to AEs. Treatment outcomes were retrospectively evaluated. RESULTS: The objective response rate (ORR) and disease control rate (DCR) for lenvatinib treatment were 25.0% and 95.0%, respectively, according to the Response Evaluation Criteria in Solid Tumors. The median progression-free survival (PFS) was 6.0 months, and the median overall survival (OS) was 10.5 months. Eleven patients experienced anorexia or fatigue, leading to a reduction in the dose of lenvatinib but not to a significant difference in the time to drug discontinuation. Importantly, there were no significant differences between the 11 anorexia/fatigue-suffering patients and the nine other patients with regard to PFS and OS. CONCLUSION: Lenvatinib can be efficacious and safe for treating advanced HCC patients previously treated with Atz/Bev, and AEs such as anorexia and general fatigue can be effectively managed without losing lenvatinib's therapeutic benefits.
  • 中岡 和徳, 橋本 千樹, 葛谷 貞二, 長坂 光夫, 舩坂 好平, 河邊 由佳, 高原 武志, 宮原 良二, 須田 康一, 廣岡 芳樹
    日本消化器がん検診学会雑誌, 61(4) 498-506, Jul, 2023  
    症例は72歳,男性。年に1度の人間ドックで施行した血液検査にてCA19-9が62.2U/mLと高値であったため,CT検査を行ったところ膵頭部に腫瘍を指摘され,精査加療目的で当院紹介受診となった。腹部造影CT検査で膵頭部に21mm大の乏血性腫瘍を認め膵癌が疑われた。同部位に対して超音波内視鏡下穿刺吸引生検法を施行し,腺癌と病理診断された。以上から膵頭部癌と診断し,手術前化学療法施行後,幽門輪温存膵頭十二指腸切除術を施行した。手術検体の病理組織学的所見では,Hematoxylin Eosin染色で低分化型腺癌成分に加え,小型円形核,淡明な胞体を有する異型に乏しい細胞が蜂巣状に増生しており,免疫染色でsynaptophysin染色,chromogranin染色が共に陽性であったことから,充実胞巣状構造の成分はneuroendocrine neoplasmと診断した。腺癌およびneuroendocrine neoplasmがそれぞれ30%以上存在していたことから膵頭部原発Mixed neuroendocrine-non-neuroendocrine neoplasmと最終診断された。(著者抄録)
  • 小林 真理子, 中野 卓二, 宮地 洋平, 田中 浩敬, 中岡 和徳, 川部 直人, 大野 栄三郎, 舩坂 好平, 中川 義仁, 葛谷 貞二, 宮原 良二, 橋本 千樹, 柴田 知行, 廣岡 芳樹
    日本消化器病学会東海支部例会プログラム抄録集, 138回 78-78, Jun, 2023  
  • 栃尾 巧, 藤井 匡, 近藤 修啓, 舩坂 好平, 中野 卓二, 田中 浩敬, 中岡 和徳, 大野 栄三郎, 葛谷 貞二, 橋本 千樹, 廣岡 芳樹
    胆と膵, 44(5) 385-392, May, 2023  
    エネルギー産生栄養素とは,たんぱく質,脂質,炭水化物に分類される宿主のエネルギーとして利用される成分である。エネルギー産生栄養素には,体に必要な筋肉,内臓,血管などさまざまな組織の構成成分を供給するとともに,脳をはじめとして生体活動を維持するために日々使用するエネルギーを供給する役割を担っている。さらに,炭水化物の一部は,食物繊維という消化酵素で分解されることなく,大腸に存在する腸内細菌の栄養素として利用される成分を含む。本稿では,エネルギー産生栄養素の代謝の代表的なプロセスを紹介するとともに食物繊維に関し最新の研究動向を紹介する。(著者抄録)
  • 藤井 匡, 栃尾 巧, 舩坂 好平, 中野 卓二, 田中 浩敬, 中岡 和徳, 大野 栄三郎, 葛谷 貞二, 橋本 千樹, 廣岡 芳樹
    胆と膵, 44(5) 393-401, May, 2023  
    ビタミンとは,三大栄養素などのエネルギー産生栄養素に比べ微量ではあるものの,人体の機能を正常に保つため必要な有機化合物である。ヒトは,三大栄養素を代謝してエネルギー貯蔵分子であるATPに変換する生体内酵素反応において,特定のビタミン(B群,C)やミネラル(鉄,マグネシウム)を必要とする。さらに,ヒトは自ら消化酵素をもたない食物繊維やポリフェノールの代謝を腸内細菌叢に依存し,それが生産するビタミンや短鎖脂肪酸などの低分子代謝物をヒトの代謝に利用している。われわれは,バランスのよい食生活を通じ,自分達の代謝に必要な三大栄養素,ビタミン,ミネラルなどを摂取することはもちろん,腸内細菌の代謝に必要な食物繊維などのプレバイオティクスも摂取する必要がある。(著者抄録)
More

Misc.

 91
  • 川部直人, 橋本千樹, 原田雅生, 有馬裕子, 西川徹, 吉岡健太郎
    臨床消化器内科, 27(11) 1467-1474, 2012  
  • 吉岡健太郎, 橋本千樹, 西川徹
    附：全国主要消化器診療施設一覧, 450-453, Dec 26, 2011  
  • Keisuke Osakabe, Naohiro Ichino, Toru Nishikawa, Hiroko Sugiyama, Miho Kato, Shiho Kitahara, Senju Hashimoto, Naoto Kawabe, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Koji Suzuki, Kentaro Yoshioka
    JOURNAL OF GASTROENTEROLOGY, 46(11) 1324-1334, Nov, 2011  
    Background Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. Methods LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. Results LS was significantly correlated with fibrosis stage (rho = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F >= 2, 10.7 kPa for F >= 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682). Conclusions LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.
  • Masao Harata, Senju Hashimoto, Naoto Kawabe, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Yuko Arima, Hiroaki Shimazaki, Tetsuya Ishikawa, Akihiko Okumura, Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa, Kentaro Yoshioka
    HEPATOLOGY RESEARCH, 41(5) 423-429, May, 2011  
    Aim: Transient elastography is a non-invasive tool to measure liver stiffness (LS), which has been reported to correlate with stage of liver fibrosis. Extrahepatic cholestasis was reported to cause elevated LS, which is considered to be attributed to the increased hydrostatic pressure in the liver. In the present study, the correlation of LS with laboratory data was investigated in extrahepatic cholestasis. The change of LS after biliary drainage was also assessed. Methods: LS was measured in 29 patients with extrahepatic cholestasis due to carcinomas in 12 and non-neoplastic diseases of biliary tract or pancreas in 17. Results: In 15 patients, LS was 11.4 kPa or higher which suggested liver cirrhosis in chronic infection of hepatitis C virus. LS significantly correlated positively with serum bilirubin levels (r = 0.726, P < 0.0001) and negatively with serum aspartate aminotransferase (AST) levels (r = -0.481, P = 0.0082) and alanine aminotransferase (ALT) levels (r = -0.631, P = 0.0002). Biliary drainage led to a reduction of bilirubin by 13.5 to 0.9 mg/dL which was significantly correlated with a reduction of LS by 14.3 to 0.5 kPa (r = 0.524, P = 0.0257). Conclusion: In extrahepatic cholestasis, the elevation of LS which is probably attributed to the increased hydrostatic pressure in the liver, correlates positively with the accumulation of bilirubin but negatively with damage of hepatocytes indicated by ALT levels. Further studies on the mechanism underlying the elevation of LS should be helpful to elucidate the pathogenesis of extrahepatic cholestasis.
  • Masao Harata, Kentaro Yoshioka, Senju Hashimoto, Naoto Kawabe, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Yuko Arima, Hiroaki Shimazaki, Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa
    HEPATOLOGY, 52(4) 481A-482A, Oct, 2010  
  • 川部直人, 橋本千樹, 村尾道人, 有馬裕子, 嶋﨑宏明, 中野卓二, 新田佳史, 原田雅生, 吉岡健太郎
    Gastroenterological Endoscopy, 52(10) 2960-2966, Oct, 2010  
    症例は76歳男性で、健診にて胆嚢結石を指摘された既往があり、近医にてC型肝炎と多発肝細胞癌(HCC)を指摘され紹介受診した。肝両葉の多発HCCにCDDP肝動注併用カテーテル的動脈下顎塞栓術計3回で腫瘍マーカーは正常化した。その後発熱と倦怠感で入院し、CTで脾周囲の低吸収域と脾実質の圧排所見、胆嚢・総胆管末端に小結石を認めた。超音波ガイド下の経皮的ドレナージで胆汁様液が穿刺され、脾周囲biloma(胆汁性嚢胞)疑いで内視鏡的逆行性胆管膵管造影(ERCP)を行った。総胆管結石と肝内胆管末梢より脾臓周囲への造影剤漏出・貯留を認め、bilomaの診断で内視鏡的胆道ドレナージチューブを挿入留置した。Biloma穿刺液からKlebsiella pneumoniaeが検出され、抗生剤投与で陰性化した。Bilomaは縮小し、内視鏡的乳頭切開術と総胆管の採石を行い、ERCPにて胆汁漏出の消失を認めた。
  • 西川徹, 杉本邦彦, 高井洋次, 加藤美穂, 杉山博子, 青山和佳奈, 鈴木亜委, 北原志穂, 吉岡健太郎, 橋本千樹, 川部直人, 原田雅生, 中野卓二, 市野直浩, 刑部恵介
    stimulated acoustic accumulation imaging INNERVISION, 25(11) 68-71, Oct, 2010  
  • Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa, Hiroko Sugiyama, Miho Kato, Shiho Kitahara, Senju Hashimoto, Naoto Kawabe, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Yuko Arima, Hiroaki Shimazaki, Koji Suzuki, Kentaro Yoshioka
    WORLD JOURNAL OF GASTROENTEROLOGY, 16(38) 4809-4816, Oct, 2010  
    AIM: To construct and evaluate a new non-invasive fibrosis index for assessment of the stage of liver fibrosis. METHODS: A new fibrosis index (Fibro-Stiffness index) was developed in 165 of 285 patients with chronic hepatitis C, and was validated in the other 120 patients where liver biopsy was performed. Its usefulness was compared with liver stiffness (LS) measured by FibroScan, the aminotransferase-to-platelet ratio index, the Forns index and the FibroIndex. RESULTS: The Fibro-Stiffness index consists of LS, platelet count and prothrombin time. The values of the Fibro-Stiffness index differed significantly between neighboring fibrosis stages except F0-F1. The area under the receiver operating characteristics curves of the Fibro-Stiffness index for prediction of F >= 2 (0.90), F >= 3 (0.90) and F = 4 (0.92) in the estimation group and those for F >= 3 (0.93) and F = 4 (0.97) in the validation group were the highest among the 5 methods examined. The accuracy of the Fibro-Stiffness index had highest values for F >= 2, F >= 3 and F = 4 in both the estimation and validation groups. The diagnostic performance for F = 4 was improved by a combination of the Fibro-Stiffness index with serum hyaluronic acid level. CONCLUSION: The Fibro-Stiffness index was constructed and validated. It showed superior diagnostic performance to other indices for F >= 2, 3 and 4. (C) 2010 Baishideng. All rights reserved.
  • 川部直人, 橋本千樹, 有馬裕子, 嶋崎宏明, 中野卓二, 村尾道人, 新田佳史, 原田雅生, 西川徹, 刑部恵介, 市野直浩, 吉岡健太郎
    消化器内科(Gastroenterology), 50(5) 453-461, May, 2010  
  • Yuko Arima, Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Kyoko Kobayashi, Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa, Akihiko Okumura, Tetsuya Ishikawa, Kentaro Yoshioka
    HEPATOLOGY RESEARCH, 40(4) 383-392, Apr, 2010  
    Aim: To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed. Methods: LS was measured by transient elastography before treatment, at end of treatment (EOT), and 1 year and 2 years after EOT in 145 patients with chronic hepatitis C treated by IFN with or without ribavirin. Results: In the patients with sustained virological response (SVR) (n = 93) and relapsers (n = 28), LS significantly decreased at EOT (median, 5.4 [interquartile range, 4.0-8.6] kilopascals [kPa], P < 0.0001 and 6.8 [4.5-8.9] kPa, P = 0.0023) and 1 year after EOT (5.3 [4.2-7.0] kPa, P < 0.0001 and 6.8 [4.5-9.3] kPa, P = 0.0204) compared with baseline (8.0 [5.0-11.9] kPa and 10.6 [7.0-16.6] kPa). In SVR patients, LS significantly decreased 2 years after EOT (5.3 [4.1-6.3] kPa) compared with baseline (P < 0.0001) and LS at EOT (P = 0.0034). Two points or greater reduction of deduced stage at last LS measurement was observed in 78% of SVR patients, 59% of relapsers and 15% of patients with non-virological response whose pretreatment deduced stages were F3-F4. Fibrosis stage, hyaluronic acid levels, duration of treatment, response to treatment and alanine aminotransferase levels were associated with a 2-point or greater decrease of deduced fibrosis stage. Conclusion: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.
  • Hiroaki Shimazaki, Yuko Arima, Takuji Nakano, Michihito Murao, Yoshifumi Nitta, Masao Harata, Naoto Kawabe, Senju Hashimoto, Kenichi Nagano, Tetsuya Ishikawa, Akihiko Okumura, Kazuhiko Hayashi, Yoshiaki Katano, Makoto Kuroda, Kentaro Yoshioka
    Acta Hepatologica Japonica, 51(4) 175-182, 2010  
    Case is a 29-yr-old man, whose complaint was abdominal pain He had photosensitivity since childhood The paternal grandfather and the younger brother have photosensitivity. In November 2001, he admitted in the other hospital with liver dysfunction and was diagnosed as erythropoietic protoporphyria (EPP). In August 2005, he admitted with abdominal pain and jaundice and recovered with antibiotics In January 2006, he was referred to our hospital with mild elevation of ALT. In November 2006 and in May 2007, he admitted in our hospital with abdominal pain and jaundice, and recovered with antibiotics In August 2008, he admitted with the same symptoms. Erythrocyte protoporphyrin and total bilirubin continually elevated. He died from liver failure in November 2008. A small portion of EPP patients suffer from liver failure. The only effective treatment for liver failure of EPP is liver transplantation, which should be considered at appropriate timing of the disease course. © 2010 The Japan Society of Hepatology.
  • 川部直人, 橋本千樹, 吉岡健太郎
    消化器科, 49(3) 262-267, Sep, 2009  
  • HARATA Masao, HASHIMOTO Senju, KAWABE Naoto, YOSHIOKA Kentaro, KURODA Makoto
    Tando, 23(4) 692-697, Jul 17, 2009  
    A 32-year-old man consulted a local hospital for epigastric pain and was diagnosed as obstructive jaundice. He was referred and hospitalized in our hospital. One year ago, he had treatment of pulmonary tuberculosis. Contrast-enhanced abdominal multi-detector row CT (MD-CT) showed a low density mass with an enhanced rim at hepatic portal region. PTBD was done and revealed a smooth narrowing of the upper part of common biliary duct. Based on these results, we suspected that an enlarged lymph node at hepatic portal region caused obstructive jaundice. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the lymph node at hepatic portal region was done. The pathology of specimen showed caseating granulomas and polymerase chain reaction analysis for tuberculosis of the specimen was positive. Thus we diagnosed as tuberculous lymphadenitis at hepatic portal region which caused obstructive jaundice. Antituberculosis medications were started and the size of the lymph node reduced gradually. After 6 months, biliary drainage tube was removed, and the patient stayed well without development of jaundice.<br>
  • Yoshifumi Nitta, Naoto Kawabe, Senju Hashimoto, Masao Harata, Naruomi Komura, Kyoko Kobayashi, Yuko Arima, Hiroaki Shimazaki, Takuji Nakano, Michihito Murao, Naohiro Ichino, Keisuke Osakabe, Hisako Aoki, Yoko Hosoe, Hiroko Sugiyama, Toru Nishikawa, Kentaro Yoshioka
    HEPATOLOGY RESEARCH, 39(7) 675-684, Jul, 2009  
    Aim: Liver stiffness (LS) measured by transient elastography (TE) has been reported to correlate with liver fibrosis, which is usually semiquantitatively assessed. In the present study, the fibrosis area was measured by image analysis software in liver biopsy specimens and its correlation with LS was assessed. Methods: LS was measured by TE in all 165 patients with chronic hepatitis C virus (HCV) infection who underwent liver biopsy consecutively in Fujita Health University Hospital from July 2004 to September 2007. Results: Fibrosis area was significantly correlated with fibrosis stage as assessed by the Metavir score (rho = 0.733, P &lt; 0.0001). The optimal cut-off value of fibrosis area was 1.6% for F &gt; or = 2, 3.1% for F &gt; or = 3, and 3.8-6.4% for F4. LS was significantly correlated with fibrosis stage (rho = 0.734, P &lt; 0.0001). The optimal cut-off value of LS was 7.1 kPa for F &gt; or = 2, 9.6 kPa for F &gt; or = 3 and 11.6-16.9 kPa for F4. Multiple linear regression analysis selected fibrosis area (P = 0.0002), alanine aminotransferase (ALT) (P = 0.0237), gamma-glutamyltransferase (gamma-GTP) (P = 0.0114), prothrombin time (P = 0.0114) and hyaluronic acid (P &lt; 0.0001) as factors correlating with LS. Conclusion: The correlation between LS and liver fibrosis was confirmed by the objective measurement of fibrosis area. ALT was significantly correlated with LS, suggesting that inflammatory activity also affects LS values. Despite some limitation, LS measurement is a useful method for the diagnosis of liver fibrosis.
  • Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Naruomi Komura, Kyoko Kobayashi, Kentaro Yoshioka
    JOURNAL OF GASTROENTEROLOGY, 44(7) 751-756, Jul, 2009  
    Background The aim of this study was to investigate the correlation between precore (PC)/basal core promoter (BCP) mutations and the viral loads or activity of hepatitis in patients with chronic hepatitis B virus (HBV) infection. Methods HBV genotypes, PC mutations, BCP mutations, HBV DNA levels, and serological markers of HBV were analyzed in all the patients with chronic HBV infection seen in Fujita Health University Hospital from June 2004 to November 2008 (n = 215). Results HBV genotype was C in 169 patients, B in 16, A in 3, F in 1, and unclassifiable in 5. Among the patients with genotype C, the prevalence of PC wild type was significantly lower in hepatitis B envelope antigen (HBeAg)(-) patients than in HBeAg(?) patients (9.5% versus 49.0%, P\0.0001). Among HBeAg(-) patients, the patients with PC wild type had significantly lower serum viral loads and alanine aminotransferase (ALT) levels compared with those with PC mutant (P\0.001). Among HBeAg(-) patients, the patients with genotype B had lower serum viral loads compared with those with genotype C (3.6 +/- 0.9 versus 4.6 +/- 1.6, P &lt; 0.05), and the prevalence of BCP wild type was significantly higher in those with genotype B than in those with genotype C (58.3% versus 10.8%, P &lt; 0.05). Conclusions Among HBeAg(-) patients with genotype C, the patients with PC wild type had significantly lower viral loads and ALT levels than those with PC mutant. This suggests that the patients with PC wild type may have better prognosis than those with PC mutant among HBeAg(-) patients with genotype C.
  • 志村 正博, 堀口 明彦, 石原 慎, 伊東 昌広, 永田 英生, 浅野 之夫, 山元 俊行, 津田 一樹, 森垣 曉子, 橋本 千樹, 加藤 良一, 花岡 良太, 宮川 秀一
    日本膵・胆管合流異常研究会プロシーディングス, 30 61-61, Sep, 2007  
  • 伊藤 良太郎, 堀口 明彦, 石原 慎, 伊東 昌広, 永田 英生, 浅野 之夫, 清水 朋宏, 津田 一樹, 神谷 博章, 松本 慎一, 宮川 秀一, 橋本 千樹, 吉岡 健太郎, 加藤 良一
    肝胆膵治療研究会誌, 5(1) 110-110, Aug, 2007  
  • HASHIMOTO Senju, HIROOKA Yoshiki, ITOH Akihiro, KAWASHIMA Hiroki, HARA Kazuo, KANAMORI Akira, UCHIDA Hiroki, GOTO Jun, NIWA Yasumasa, YOSHIOKA Kentarou, GOTO Hidemi
    Choonpa Igaku, 33(4) 483-492, Jul 15, 2006  
    We describe the basics, devices and utility of three-dimensional transabdominal ultrasonography (3DUS). 3DUS volume measurements are accurate regardless of gallbladder configuration. 3DUS may be the most reliable method to estimate gallbladder motility. Virtual endoscopy imaging using 3DUS made it easier to understand three-dimensional shapes and surface conditions of the lesions, and it was more objective and stringent than conventional ultrasonography. We expect that 3DUS will contribute to the advance of ultrasonographic diagnoses of bilio-pancreatic diseases.
  • UCHIDA Hiroki, HIROOKA Yoshiki, ITO Akihiro, HASHIMOTO Senju, KAWASHIMA Hiroki, HARA Kazuo, KANAMORI Akira, GOTO Jun, NIWA Yasumasa, GOTO Hidemi
    32 S239, Apr 15, 2005  
  • HIROOKA Yoshiki, ITOH Akihiro, HASHIMOTO Senju, OHMIYA Naoki, NIWA Yasumasa, GOTO Hidemi
    19(6) 598-607, Dec 28, 2004  
  • HARA Kazuo, HIROOKA Yoshiki, ITOH Aldhiro, HASHIMOTO Senju, KAWASHIMA Hiroki, KANAMORI Akira, UTIDA Hiroki, GOTO Jun, OHMIYA Naoki, NIWA Yasumasa, GOTO Hidemi
    18(5) 614-619, Dec 28, 2004  
  • HIROOKA YOSHIKI, ITOH AKIHIRO, HASHIMOTO SENJU, NIWA YASUMASA, GOTO HIDEMI
    Dig Endosc, 15 S51-S58, Jul 1, 2003  
  • 29(5) 70-72, May, 2002  
  • HIROOKA YOSHIKI, GOTO HIDEMI, ITO AKIHIRO, HASHIMOTO SENJU, HAYAKAWA TETSUO
    13 S49-S53, Jul 1, 2001  
  • HIROOKA Y., GOTO H., ITOH FJSUM A., HASHIMOTO S., HAYAKAWA T.
    28(3) J302, Apr 15, 2001  
  • HIROOKA Y., GOTO H., ITOH FJSUM A., HASHIMOTO S., HAYAKAWA T.
    28(3) J317, Apr 15, 2001  
  • HASHIMOTO S.
    28(3) J377, Apr 15, 2001  
  • NIWA K., GOTOH H., HIROOKA Y., ITOH A., HASHIMOTO S., HIRAI T., TAKEDA K., HAYAKAWA T., KIMOTO E.
    28(3) J579, Apr 15, 2001  
  • HASHIMOTO S., GOTO H., HIROOKA Y., ITOH A., ISHIGURO Y., KOJIMA S., HIRAI T., HAYAKAWA T., NAITOH Y., KIMOTO E.
    27(4) 395-395, Apr 15, 2000  
  • KOJIMA S., HIROOKA Y., ITOH A., ISHIGURO Y., HASHIMOTO S., HIRAI T., HAYAKAWA T., GOTO H., NAITOH Y., KIMOTO E.
    27(4) 540-540, Apr 15, 2000  
  • HIRAI T., HIROOKA Y., ITOH A., ISHIGURO Y., KOJIMA S., HASHIMOTO S., HAYAKAWA T., GOTO H., NAITOH Y., KIMOTO E.
    27(4) 557-557, Apr 15, 2000  
  • ANDO N., HIROOKA Y., NIWA Y., ITOH A., ISHIGURO Y., HASHIMOTO S., HIRAI T., GOTO H., HAYAKAWA T.
    27(4) 577-577, Apr 15, 2000  
  • HIROOKA Y., ITOH A., ISHIGURO Y., KOJIMA S., HASHIMOTO S., HIRAI T., HAYAKAWA T., GOTO H., NAITOH Y., KIMOTO E.
    27(4) 587-587, Apr 15, 2000  
  • ITOH A., GOTO H., HIROOKA Y., ISHIGURO Y., KOJIMA S., HASHIMOTO S., HAYAKAWA T., NAITOH Y., KIMOTO E.
    26(4) 333-333, Apr 15, 1999  
  • KOJIMA S., GOTO H., HIROOKA Y., ITOH A., ISHIGURO Y., HASHIMOTO S., HIRAI T., HAYAKAWA T., NAITOH Y., KIMOTO E.
    26(4) 337-337, Apr 15, 1999  
  • HIROOKA Y., GOTO H., ITOH A., ISHIGURO Y., KIJIMA S., HASHIMOTO S., HIRAI T., HAYAKAWA T., NAITOH Y., KIMOTO E.
    26(4) 458-458, Apr 15, 1999  
  • HASHIMOTO S., GOTO H., HIROOKA Y., ITOH A., ISHIGURO Y., KOJIMA S., HIRAI T., HAYAKAWA T., NAITOH Y., KIMOTO E.
    26(4) 423-423, Apr 15, 1999  
  • 廣岡 芳樹, 後藤 秀実, 伊藤 彰浩, 石黒 義浩, 小島 伸哉, 橋本 千樹, 平井 孝典, 早川 哲夫, 内藤 靖夫
    BME : bio medical engineering, 13(4) 24-30, Apr, 1999  
  • HIROOKA Y., GOTO H., ITOH A., HAYAKAWA S., WATANABE Y., KOJIMA S., HASHIMOTO S., HAYAKAWA T., NAITOH Y., KIMOTO E.
    J Med Ultrasonic, 24(9) 193-193, Sep 15, 1997  
  • HASHIMOTO S., GOTO H., HIROOKA Y., ITOH A., HAYAKAWA S., WATANABE Y., ISHIGURO Y., HAYAKAWA T., NAITOH Y., KIMOTO E.
    24(9) 172-172, Sep 15, 1997  
  • HAYAKAWA S., GOTO H., HIROOKA Y., ITOH A., WATANABE Y., ISHIGURO Y., KOJIMA S., HASHIMOTO S., HAYAKAWA T., NAITOH Y., KIMOTO E.
    24(9) 171-171, Sep 15, 1997  

Presentations

 98
More

Research Projects

 2

その他教育活動上特記すべき事項

 6
  • 件名（英語）
    第23回医学教育ワークショップ
    終了年月日（英語）
    2008/05/17
    概要（英語）
    「ＣＢＴ試験問題作成」に参加した。
  • 件名（英語）
    第25回医学教育ワークショップ　
    終了年月日（英語）
    2008/09/06
    概要（英語）
    「卒業試験臨床長文問題ブラッシュアップ」に参加した。
  • 件名（英語）
    第27回医学教育ワークショップ　
    終了年月日（英語）
    2009/04/12
    概要（英語）
    「小グループ学習の充実」に参加した。
  • 件名（英語）
    第30回医学教育ワークショップ　
    終了年月日（英語）
    2009/08/29
    概要（英語）
    「計算問題　多肢選択問題 臨床長文問題ブラッシュアップ」に参加した。
  • 件名（英語）
    第33回医学教育ワークショップ　
    終了年月日（英語）
    2010/05/15
    概要（英語）
    「ＣＢＴ試験問題作成」に参加した。
  • 件名（英語）
    第35回医学教育ワークショップ
    終了年月日（英語）
    2010/08/28
    概要（英語）
    「多肢選択問題 臨床長文問題ブラッシュアップ」に参加した。
To the list screen